Summary Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two longestablished (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosensitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an ICso value, the drug concentration causing 50% inhibition of clonogenic survival. IC5, values were obtained from dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(aD + PD2)]. The IC,, values of the two platinum derivatives varied considerably. The values for cisplatin varied between 0.022 1g ml-' and 0.56 jug ml' and the corresponding values for carboplatin were 0.096-1.20 1g ml-'. The range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow.
The first platinum-containing drug, cisplatin, was introduced to clinical use in the 1970s. It is widely used in the treatment of solid malignancies, including tumours of the female genital tract. Cisplatin is highly toxic, with nephrotoxicity and neuropathy being the dose-limiting effects. The secondgeneration drug, carboplatin, was developed in the 1980s mainly to reduce side-effects. Carboplatin has low nephrotoxicity and its major toxic effect is myelosuppression including leucopenia and thrombocytopenia. Cisplatin and carboplatin have also been studied for their ability to function as radiosensitisers both in vitro and in vivo (Dewit 1987; Pekkola-Heino et al., 1992a; Nguyen et al., 1993) . Furthermore, promising clinical results of concomitant use of radiation and platinum derivates have been obtained, especially in the treatment of head and neck cancers (Jacobs et al., 1989; Choi et al., 1991) .
In the treatment of endometrial carcinoma chemotherapy is used in advanced or recurrent cases. The treatment schedules consist of 1-3 drugs, and platinum derivatives are used either as single agents or as a part of a combined chemotherapy regimen. When cisplatin is used as single-agent therapy for advanced or recurrent endometrial carcinoma response rates of 4-42% have been reported (Thigpen et al., 1987) . Total response rates of 33-47% have been achieved using the combination of cisplatin, doxorubicin and cyclophosphamide (Hoffman et al., 1989; Dunton et al., 1991) .
In vitro studies on the chemosensitivity of endometrial cancer are scanty. In addition, comparative evaluations are random; some of the published studies include cisplatin, but not carboplatin (Jones et al., 1987; Nguyen et al., 1991) . Experiments with animals have shown high platinum concentrations in the uterus after intravenous administration (Litters et al., 1976 (Litters et al., , 1977 . Recent clinical experience with advanced cervical carcinoma suggests a positive correlation between responses to chemotherapy and radiotherapy (Kirsten et al., 1987) . Also, in vitro studies performed with cervical cancer cell lines support this clinical finding (Kelland & Tonkin, 1989 Cell culture Prior to the experiments the cells were maintained in logarithmic growth in T25 culture flasks by passing weekly in Dulbecco's modified Eagle minimal essential medium (DMEM) containing 2 mM L-glutamine, 1% non-essential amino acids, 100 U ml-' penicillin, 100 U ml-' streptomycin and 10% fetal bovine serum (FBS) . Cells in mid-logarithmic growth (40-60% confluency) were used for experiments and fed with fresh medium on the day before plating. Drug preparation Cisplatin (Platinol) 0.5 mg ml-' was diluted with growth medium to get a stock solution 100 fig ml-' and sterilised by pressing through a 0.22 tLm filter. Final cisplatin dilutions of 0.02-2.0 g ml-' were used, and new stock solutions were made for each experiment. Rantanen et al. (1993b) aUnder characterisation (S. Grenman).
Carboplatin (Paraplatin) was dissolved in growth medium as a stock solution of 100 Ltg ml-' and sterilised by pressing through a 0.22 tLm filter. The final dilutions 0.05-2.5 sg ml-' were made immediately before use, and new stock solutions were made for each experiment.
Clonogenic assay
The 96-well clonogenic assay based on limiting dilutions was used. The assay has been described earlier in detail Rantanen et al., 1993b) . A minimum of three experiments including duplicate plates were performed for each cell line. The cells were harvested with trypsin-EDTA to obtain a single-cell suspension, counted and diluted in Ham's F-12 medium containing 15% fetal bovine serum (FBS) or newborn bovine serum (NBS). With a cell suspension containing 4,167 cells ml-' and diluted in 25 ml of growth medium, a concentration of two cells per well is achieved by applying 100 ftl to each well with an octapipette (Costar). The number of cells plated per well was adjusted according to the plating efficiency (PE) of the cell line. After plating into the 96-well plate the cells were allowed to attach for 24 h at 37°C in an incubator with a water vapoursaturated atmosphere containing 5% carbon dioxide.
Twenty-four hours after plating, 100 #l of growth medium containing the desired concentration of cisplatin or carboplatin was added to the wells.
To obtain dose-response curves for cisplatin and carboplatin, the drug solutions were allowed to remain in the plates during the whole incubation period. The plates were kept in the incubator for 4 weeks, after which time the number of wells containing coherent, living colonies (a colony consisting of 32 cells or more) was counted using an inverted phase-contrast microscope.
Data analysis Plating efficiency (PE) was calculated using the formula 
Results
The PE values of the cell lines are listed in Table I . Doseresponse curves for each cell line were obtained by fitting the data points to the linear quadratic equation (Figure la-h (Rantanen et al., 1992 (Rantanen et al., , 1993a .
Discussion
In vitro data on the chemosensitivity of endometrial cancer are scanty partly because of the lack of suitable cell lines. We have recently established and characterised numerous endometrial adenocarcinoma cell lines (Grenman et al., 1988b (Grenman et al., , 1990 and used them for testing in vitro radiosensitivity of this tumout type (Rantanen et al., 1992 (Rantanen et al., , 1993a . These studies have been performed using the 96-well-plate clonogenic assay, which has proven to be suitable for testing both radiosensitivity and chemosensitivity of adenocarcinoma as well as squamous cell carcinoma cell lines (Grenman et al., 1988a (Grenman et al., , 1991 Pekkola-Heino et al., 1989 , 1992a Rantanen et al., 1992 Rantanen et al., , 1993a . In this study we The cytotoxic effects of cisplatin and carboplatin were compared in a variety of cell lines, including ovarian carcinoma cell lines (Hills et al., 1989; Fanning et al., 1990; Dittrich et al., 1993) and stomach and lung cancer cell lines (Takahashi et al., 1987) . The results obtained from in vitro chemosensitivity testing vary considerably and because of different methods and exposure times they cannot be directly compared. Jones et al. (1987) determined the chemosensitivities of fresh human endometrial tumour samples with a soft-agar clonogenic assay. They used continuous drug exposure and achievable peak plasma levels (2.5 l.g ml-') and one-tenth peak plasma levels (0.25 jg ml-'). Twenty-seven of 30 endometrial adenocarcinoma samples demonstrated 70% or more reduction in colony formation with peak plasma level of cisplatin, and the corresponding number for onetenth peak plasma level was 10 out of 21. Nguyen et al. (1991) evaluated the chemosensitivity of uterine cancer cell lines using ATP bioluminescence assay and 90 min exposure to cisplatin or carboplatin. IC50 values for carboplatin were higher in three cases (x 1.1-2.1) and IC50 values for cisplatin were higher in three cases (x 1.3-10.0).
Our results show great variation in the IC50 values of platin ICso to cisplatin ICso varied in our material from 1.5:1 to 4.4:1. These data fit with the current clinical practice of using carboplatin and cisplatin in the ratio of 3-4:1. However, Terheggen et al. (1988 Terheggen et al. ( , 1991 reported that on a molar basis 6-18 times more carboplatin than cisplatin is required to obtain the same level of DNA and platinum interaction products in cancer patients. Their in vitro studies indicated a direct correlation between cisplatin-and carboplatin-induced cell kill and DNA adduct production (Terheggen et al., 1990) . The predictive value of DNA adduct production is still unevaluated, and further clinical studies are needed to confirm the equivalent clinical doses with regard to efficacy of these two platinum analogues.
In our results the difference between UT-EC-2A and UT-EC-2B IC50 values for cisplatin and carboplatin is of interest.
The UT-EC-2A cell line was established from the primary tumour and the UT-EC-2B cell line was established from a supraclavicular metastasis after the donor had received six courses of chemotherapy including cisplatin. Cisplatininduced growth inhibition was remarkable in UT-EC-2A cultures, whereas the UT-EC-2B cell line was the most resistant cell line to cisplatin. UT-EC-2B cells were also found to be highly resistant to carboplatin. These findings could be explained by selection of platinum-resistant cells in the donor's tumour during treatment with platinum-containing chemotherapy.
Results obtained by Kelland and Tonkin (1989) suggest a positive correlation between the chemo-and radiosensitivity of squamous cell carcinoma lines of the uterine cervix. Furthermore, a positive correlation between response to chemotherapy and subsequent response to radiotherapy has been reported in a group of patients with locally advanced cervical cancer (Kirsten et al., 1987) . We have previously tested the radiosensitivity of the endometrial cancer cell lines used in this study (Rantanen et al., 1992 (Rantanen et al., , 1993a . Therefore, it was of interest to compare the chemosensitivity and radiosensitivity of individual cell lines. We could not find a correlation between cisplatin and carboplatin sensitivities and the intrinsic radiation sensitivity of the eight endometrial cancer cell lines.
Concomitant use of radiation and chemotherapy in the treatment of radioresistant tumours is one possibility to achieve better outcome in these patients. Owing to the widespread clinical use of platinum analogues in the treatment of advanced or recurrent endometrial cancer, it seems logical to evaluate their use also as radiosensitisers. Before planning schedules for chemoradiotherapy it is important to know the in vitro sensitivities of the drugs used for the tumour type in question. Without basic knowledge obtained from in vitro studies it is difficult to determine optimal doses and timing between radiation and the exposure to chemotherapeutic agent.
